Cargando…
Rivaroxaban for the Treatment of Pulmonary Embolism
With the advent of new oral anticoagulants (NOACs) for the treatment of deep-vein thrombosis (DVT) and/or pulmonary embolism (PE), a new era of oral anticoagulation for patients with venous thromboembolism (VTE) has begun. Rivaroxaban is the first NOAC to receive regulatory approval for the acute an...
Autores principales: | Vanassche, Thomas, Verhamme, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706730/ https://www.ncbi.nlm.nih.gov/pubmed/23807375 http://dx.doi.org/10.1007/s12325-013-0041-4 |
Ejemplares similares
-
Rivaroxaban treatment for young patients with pulmonary embolism (Review)
por: Wu, Haidi, et al.
Publicado: (2020) -
Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors
por: De Vlieger, Jan, et al.
Publicado: (2017) -
Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019) -
Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
por: Song, Zi-Kai, et al.
Publicado: (2020) -
Prevalence of Acute Pulmonary Embolism at Autopsy in Patients With COVID-19
por: Zuin, Marco, et al.
Publicado: (2022)